RxDoctor Payments Data

Aron Kumar Reddy, MD

Neurology · San Antonio, TXNPI 1255533592

Payments from drug & device makers

$2,470in general payments, 2019–2025

Across 142 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$222
  • Axsome Therapeutics, Inc.$160
  • ARS Pharmaceuticals Operations, Inc.$124
  • Acadia Pharmaceuticals Inc$122
  • Teva Pharmaceuticals USA, Inc.$68
  • plus $497 from 15 others

What the payments were for

  • Food & beverage$2,45899%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,470 in reported general payments places this provider in the 45th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$140,995
Medicare patients
528
Services billed
9,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NeuproRotigotine69$66,838
BotoxOnabotulinumtoxina36$47,976
QuliptaAtogepant35$46,509
Aimovig AutoinjectorErenumab-Aooe49$45,965
Emgality PenGalcanezumab-Gnlm47$37,659
HorizantGabapentin Enacarbil27$31,957
UbrelvyUbrogepant30$31,588
Nurtec OdtRimegepant Sulfate22$24,878
Oxtellar XrOxcarbazepine13$21,836
RytaryCarbidopa/Levodopa20$20,906
EliquisApixaban19$15,290
Glatiramer Acetate11$13,599
Carbidopa-LevodopaCarbidopa/Levodopa320$6,377
Lacosamide82$5,611
Memantine Hcl169$4,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Qulipta, Ubrelvy$1,278$126,074101 claims
PfizerNurtec Odt, Eliquis$222$40,16841 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$48$22,64853 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$42$21,83613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,246 neurology providers in Texas.

Other neurology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →